MedPath

Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome

Phase 2
Terminated
Conditions
Neonatal Abstinence Syndrome
Interventions
Registration Number
NCT03134703
Lead Sponsor
Johns Hopkins All Children's Hospital
Brief Summary

This is a non-randomized, un-blinded feasibility study project comparing the Length of Stay (LOS) of Neonatal Intensive Care Unit (NICU) infants diagnosed with Neonatal Abstinence Syndrome (NAS) treated with methadone with historical data and a comparison group of NICU NAS infants treated with a different narcotic agent.

Detailed Description

For the time frame July 1, 2013 through September 30, 2014, 300 infants with NAS have been cared for in the JHACH NICU with an average length of stay of 30 days. Such a prolonged length of stay has a negative impact on maternal/infant bonding. In addition, infants suffering from NAS have poor regulatory mechanisms and are invariably hard to care for and difficult to console, and they provide an emotional challenge to their caretakers. This challenge becomes even more significant when the caretaker is the mother who is suffering from addiction and is already emotionally compromised by feelings of depression, anxiety, guilt or insecurity. Attachment is an ongoing process and the quality of the relationship between mother and her infant directly influences the structure of the child's affective ties and overall organization of responses to environment. This mother-infant bond sets the stage for understanding and identifying the infant's needs and reciprocal parental response to those needs. Maternal emotional unavailability has potentially serious effects on the long term mother-child relationship, and on the child's development.

This project provides a novel approach and an alternative care plan for infants with NAS. It is funded by the State of Florida and allows to: 1) educate and empower a specified population of mothers who are undergoing institutionalized rehabilitation and whose infant needs treatment for NAS; 2) safely transition the infants home for final wean of their pharmacologic treatment; 3) provide regular developmental follow up for these infants through our NICU follow up clinic, hence identifying and quickly responding to neuro-developmental delays.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
11
Inclusion Criteria
  1. Baby is diagnosed with neonatal abstinence syndrome;
  2. Newborns ≥ 37 0/7 weeks gestation;
  3. Newborns transferred to JHACH within 72 hours from birth;
  4. Newborns ≥ 2.5 kg weight at birth;
  5. Informed parental consent.
Exclusion Criteria
  1. Infant not requiring pharmacologic treatment for NAS;
  2. Major congenital anomalies;
  3. Major concomitant medical illness including planned antibiotic treatment for greater than 3 days or NPO status;
  4. Infants who are being placed for adoption;
  5. Infants in significant pain requiring narcotic medication for comfort (for example those with a fracture);
  6. Mother with hearing or language impairment;
  7. Infants known upon admission who will be placed into state custody or sheltered.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Methadone Treatment GroupMethadoneNAS infants treated for withdrawal symptoms with methadone
Comparison GroupMorphineNAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
Primary Outcome Measures
NameTimeMethod
Length of Stay (LOS)25 days

Compare the LOS of Neonatal Intensive Care Unit (NICU) infants with Neonatal Abstinence Syndrome (NAS) treated with methadone with historical data and a comparison group of NICU NAS infants treated with a different narcotic agent.

Secondary Outcome Measures
NameTimeMethod
Readmission to HospitalWithin 30 days of discharge

Number of hospital readmissions

Maternal Bonding Measured With The Postpartum Bonding Questionnaire (PBQ)inpatient and at 6-8 weeks of age

The Postpartum Bonding Questionnaire (PBQ) is a self-rating questionnaire designed to detect disorders of the mother-infant relationship. The questionnaire has 25 statements, each with six alternative responses ranging from 0 (always) to 5 (never). For the PBQ, scores are summated for each factor, with a high score indicating concern for bonding. The PBQ yields a total score between 0 to 125. Positive responses are scored from 0 ('always') to 5 ('never'). Negative responses, are scored from 5 ('always') to 0 ('never').

Factor 1 (impaired bonding) is based on 12 questions, with a score range 0-60 (0-11=normal; 12 \& above=high).

Factor 2 (rejection \& anger) is based on 7 questions with a score range 0-35 (0-16=normal; 17 \& above=high).

Factor 3 (anxiety about care) is based on 4 questions with a score range 0-20 (0-9=normal; 10 \& above =high).

Factor 4 (risk of abuse) is based on 2 questions, with a score range 0-10 (0-2=normal; 3 \& above =high).

Maternal Depression Measured With The Edinburgh Postnatal Depression Scale (EPDS)While inpatient and at 6-8 weeks of age

The Edinburgh Postnatal Depression Scale (EPDS) was developed for screening postpartum women in outpatient, home visiting settings, or at the 6-8 week postpartum examination. The EPDS is a 10-item questionnaire with responses scored 0, 1, 2, or 3 according to increased severity of the symptom. The maximum total score is 30 while the minimum score is 0. A score of 10 or greater, as well as any answer choice other than "never" on question #10 (suicidal thoughts) of the EPDS are indicative of depressive symptomatology.

Breast Milk30 days of age

Compare the incidence of providing breast milk (\> 50% of nutritional needs) at 30 days of age between methadone treated and non-treated infants

Infant Development4, 8 and 12 months of age

Assess the age appropriate infant development at 4, 8 and 12 months of age among the methadone treatment group using the Ages and Stages-based questionnaires (ASQ). The questionnaires are screening tools designed to identify infants at risk for developmental delays through caregivers' provision of quantitative information regarding their infant's development. In the ASQ, higher scores indicate more positive outcomes. The ASQ covers 5 areas of development: communication, gross motor, fine motor, problem solving, and personal-social. Scores for each area should fall between 0-60.

Scoring:

0-30 = further assessment with a professional may be needed 30-40 = learning activities \& monitoring are indicated 45-60 = child development appears to be on schedule

Screened vs. EligibleAfter accrual of the first 50% of participants & after accrual of the second 50% of participants, and at completion of the trial.

Determine the response percentage of mothers who are screened as eligible by PAR officials and who agree to participate in the demonstration project

Attrition RateAfter accrual of the first 50% of participants, after accrual of the second 50% of participants, and at completion of the trial.

Assess the drop out percentage of mothers who agree to participate but do not follow through with home discharge for continued care

Home CareAfter accrual of the first 50% of participants, after accrual of the second 50% of participants, and at completion of the trial

Quantitate the proportion of mothers who feel comfortable with home care of their infant at discharge

Readiness of Mothers to Assess InfantAfter accrual of the first 50% of participants, after accrual of the second 50% of participants, and at completion of the trial.

Monitor the readiness of mothers to assess infant on 3 to 4 hours intervals while at home

Compliance With Pediatrician VisitsAfter accrual of the first 50% of participants, after accrual of the second 50% of participants, and at completion of the trial.

Determine the compliance rate with the Johns Hopkins All Children's Hospital (JHACH) pediatrician visits.

Trial Locations

Locations (1)

Johns Hopkins All Children's Hospital

🇺🇸

Saint Petersburg, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath